Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 17/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 17/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 2/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 2/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467604 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL29355995 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL31060883 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL15526774 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL19530328 | 0.91 | BRAF (0.84) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4134773 | 0.91 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4134774 | 0.91 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL10000524 | 0.91 | BRAF (0.83) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4137485 | 0.90 | BRAF (0.82) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4137490 | 0.90 | BRAF (0.82) | BRAFMAPK3MAPK1BMPR1BCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119979466-A | Serum-free culture method for inducing hUC-MSCs to be converted into hiPSCs by small molecular compounds | 中国科学院广州生物医药与健康研究院 | 2025-05-13 | — | — | CN | claimed |
| US-12195771-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | claimed |
| CN-118147053-A | Culture system, kit and method for inducing mesenchymal stem cells | 成都赛济元生物医药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116981768-A | Reprogramming human somatic chemistry into pluripotent cells | 北京大学 | 2023-10-31 | — | — | CN | claimed |
| US-20230277677-A1 | POLYMERIC CONJUGATES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-09-07 | — | — | US | claimed |
| EP-3426254-B1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2023-06-07 | — | — | EP | claimed |
| US-20220195408-A1 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-06-23 | — | — | US | claimed |
| US-10478446-B2 | Compounds for use in polycystic kidney disease | FONDAZIONE CENTRO SAN RAFFAELE OFFICE OF BIOTECHNOLOGY TRANSFER (IT) | 2019-11-19 | — | — | US | claimed |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | Université Libre de Bruxelles (BE) | 2017-06-15 | — | — | US | claimed |
| WO-2013165320-A1 | TREATING CANCER BY INCREASING EXPRESSION OF SOCS6 | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-11-07 | — | — | WO | claimed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | claimed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | claimed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277677-A1 | POLYMERIC CONJUGATES AND USES THEREOF | CD44, DCLRE1A, CD74 | BRAF 1052/4885MAPK3 2718/4885MAPK1 3732/4885 |
| US-20170165240-A1 | NEW STRATEGIES FOR TREATING MELANOMA | TP53, BRAF, TP53BP1 | BRAF 2/4885MAPK3 494/4885MAPK1 816/4885 |
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 55/4885MAPK1 57/4885 |
| US-10478446-B2 | Compounds for use in polycystic kidney disease | PKD1, PKD2, GLS | BRAF 861/4885MAPK3 100/4885MAPK1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.